Aligos Therapeutics, Inc. Increase (Decrease) in Other Operating Liabilities
Aligos Therapeutics, Inc. (ALGS) reported Increase (Decrease) in Other Operating Liabilities of -$47.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-06
- Aligos Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was $0.00.
- Aligos Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was -$47.00K.
- Aligos Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2023-12-31 was $0.00.
- Aligos Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Aligos Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was $46.00K.
- Aligos Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2022 was -$133.00K.
- Aligos Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2021 was -$245.00K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$47.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$47.00K 10-Q · filed 2026-05-07 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $46.00K 10-K · filed 2025-03-10 | ||
| 2023-09-30 | $46.00K 10-Q · filed 2024-11-06 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | -$133.00K 10-K · filed 2024-03-12 | |||
| 2022-03-31 | $1.00K 10-Q · filed 2023-05-04 | -$133.00K derived: sum of 2 quarters · filed 2023-05-04 | -$132.00K derived: sum of 3 quarters · filed 2023-05-04 | -$133.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$133.00K derived: sum of 2 quarters · filed 2023-03-09 | -$134.00K derived: sum of 3 quarters · filed 2023-03-09 | -$245.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | -$111.00K 10-Q · filed 2022-11-02 | |
| 2021-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$112.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$111.00K 10-Q · filed 2022-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |